NUS scientists discover control mechanism that regulates traffic across blood vessels

NUS scientists have discovered a control mechanism that regulates the traffic of cells and substances across blood vessels. This effect can have significant impact on cancer metastasis.

NUS scientists discover control mechanism that regulates traffic across blood vessels

Nanoparticles are being used in various biomedical applications, including the diagnosis and treatment of cancer. Drug releasing nanoparticles could be programmed to deliver drugs locally at the tumor site. However, recent studies have shown that these nanoparticles can lead to the formation of micrometre-sized gaps in the walls of blood vessels, making them “leaky”. In cancer patients, these gaps could make it easier for surviving cancer cells to escape from their primary sites into other parts of the body.

A research team comprising Prof HO Han Kiat from the Department of Pharmacy, NUS and Prof David LEONG from the Department of Chemical and Biomolecular Engineering, NUS discovered that Angiopoeitin-1 (a type of protein) can help to close the gaps in the blood vessels caused by nanoparticles and reduce their permeability. This, in turn, controls the passage of substances and molecules through the walls of the blood vessels. By adjusting the amount of Angiopoeitin-1 in the body, the researchers found that they can limit and reverse the “leakiness” induced in blood vessels caused by nanoparticles in biomedical applications.

In their experiments, the research team administered breast cancer cells beneath the skin of murine models and then introduced titanium dioxide nanoparticles into their blood vessels. They established that the nanoparticles increased the leakage of cancer cells into the blood vessels. This leakage effect can enhance the movement of circulating cancer cells to distant tissues, which may result in the formation of new secondary cancer sites previously not accessible to the cancer cells.

Following up on this, the team found that Angiopoeitin-1 acts as a growth factor to TIE2, a cell surface regulator found naturally in our blood vessels. When there are more Angiopoeitin-1, TIE2 protein is localized and stimulated to close up the gaps in the blood vessels which could be caused by the nanoparticles. This in turn reduces the permeability of the blood vessels and limits the amount of cancer cells leaking into the blood stream.

The study showed that Angiopoeitin-1 could potentially be used as a counter mechanism to limit and reverse the leakiness induced by nanoparticles. This helps to decrease the extravasation and transportation of cancer cells to other tissues in cancer patients."

Prof HO Han Kiat, Department of Pharmacy, NUS

Proposed mechanism of Angiopoeitin-1 (Ang-1) induced anti-permeability effect in human microvascular endothelial cells. The image on the left shows blood vessels cells that are stained to identify the location of the protein TIE2. When the activator Angiopoeitin-1 (Ang-1) is applied, TIE2 are localized near the cell surface where Ang1-Tie2 forms a bridge that holds cells together. In subsequent experiments, it is demonstrated that Ang1 binding could mediate cellular changes through increasing either phosphorylation of Akt or Erk which then helps to stabilize the microtubules to maintain cellular structure.

Source:
Journal references:

Peng, F. et al. (2019) Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness. Nature Nanotechnology. doi.org/10.1038/s41565-018-0356-z.

Tee, J.K. et al. (2019) Angiopoietin-1 accelerates restoration of endothelial cell barrier integrity from nanoparticle-induced leakiness. Nanotoxicology. doi.org/10.1080/17435390.2019.1571646.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Incorrect arm positioning inflates blood pressure readings, risking misdiagnosis